AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 9,639 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 9,639 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $45.56, for a total value of $439,152.84. Following the completion of the transaction, the insider owned 9,157 shares of the company’s stock, valued at approximately $417,192.92. This represents a 51.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AnaptysBio Stock Performance

NASDAQ ANAB traded down $1.41 on Thursday, hitting $43.80. The stock had a trading volume of 1,747,008 shares, compared to its average volume of 768,760. The firm has a 50-day moving average of $42.31 and a 200-day moving average of $31.22. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $52.47. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -15.53 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The company had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. As a group, research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its Board of Directors has initiated a share buyback plan on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

ANAB has been the topic of a number of recent analyst reports. Stifel Nicolaus lowered their target price on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. HC Wainwright decreased their price target on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Monday, November 24th. Truist Financial lifted their price objective on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Barclays cut their target price on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Finally, Wall Street Zen upgraded AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $60.40.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. grew its holdings in AnaptysBio by 4,852.7% in the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares during the period. Woodline Partners LP boosted its position in shares of AnaptysBio by 63.1% in the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after purchasing an additional 305,950 shares in the last quarter. 683 Capital Management LLC grew its stake in shares of AnaptysBio by 155.6% in the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after buying an additional 304,373 shares during the last quarter. JPMorgan Chase & Co. increased its position in AnaptysBio by 1,631.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after buying an additional 233,325 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in AnaptysBio by 145.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company’s stock valued at $11,343,000 after buying an additional 219,648 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.